[Bladder carcinoma: therapeutic concept of the Urology Department of the University Hospital, Mainz].
A therapeutic concept based on tumor staging and grading is presented: T0N0M0 - urine cytology positive - cystoscopy every 3 months. Transitional cell carcinoma (90%): T(iS)N0M0 - carcinoma in situ - cystoscopic biopsy every 3 months. Cystectomy with commencing tumor infiltration. T1N0M0 (80% of all bladder tumors): T1N0M0G0 - TUR; cystoscopy every 3 months. T1N0M0G1-3 - TUR; control-TUR 6 weeks later with systematic biopsy. G3 with tumor recurrence - cystectomy. T2N0/N1M0; G1-2 - TUR; local chemotherapy (adriamycin). G3 - cystectomy; high voltage treatment in inoperable patients. T4NxMx - symptomatic-palliative therapy: TUR, urinary diversion. Squamous cell carcinoma (2-5%): as transitional cell carcinoma; with high voltage therapy adjuvant chemotherapy using bleomycine. Adenocarcinoma (2-3%): as transitional cell carcinoma; cystectomy including part of the anterior abdominal wall and umbilicus. Immunostaging (assessment of the immunocompetence) should be part of the diagnostic procedures and follow-up examination.
D000230:Adenocarcinoma / Q000628:therapy; D001706:Biopsy; D001761:Bleomycin / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000628:therapy; D003558:Cystoscopy; D005860:Germany, West; D006801:Humans; D008722:Methods; D010347:Patient Care Planning; D011882:Radiotherapy, High-Energy; D001743:Urinary Bladder / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*; D014547:Urinary Diversion
D001761:Bleomycin
Blasencarcinom: Therapeutisches Konzept der Urologischen Universitätsklinik Mainz.